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Plasminogen activator inhibitor-1 expression is regulated by tubulointerstitial fibrosis [1–3]. The accumulation of ex-
the angiotensin type 1 receptor in vivo. tracellular matrix (ECM) in vascular and renal tissue is
Background. The fibrinolytic system plays an important role a product of both increased matrix synthesis and reducedin degrading fibrin-rich thrombi and in vascular and tissue
ECM degradation. The cytokines and growth factor-likeremodeling. Elevated levels of plasminogen activator inhib-
effects of angiotensin (Ang) II, which are largely medi-itor-1 (PAI-1) can reduce the efficiency of the endogenous
fibrinolytic system. Angiotensin (Ang) has been shown to regu- ated via the Ang II type 1 AT1 receptor [4], lead to
late PAI-1 expression via the Ang type 1 (AT1) receptor in increased ECM deposition. Recent studies suggest that
some tissues and via the AT4 receptor in cultured endothelium.
Ang II may also play a role in regulating the activityThe purpose of this study was to examine the tissue-specific
of proteolytic pathways involved in matrix degradation.pattern of PAI-1 expression in response to infusion of Ang II
in vivo. Ang II regulates the expression of protease inhibitors
Methods. Adult male Sprague-Dawley rats (N 5 5 in each that reduce endogenous proteolytic housekeeping activ-
group) were treated with four hours of intravenous infusions ity, including plasminogen activator inhibitor-1 (PAI-1)of Ang II or vehicle control while mean arterial pressure
and tissue inhibitor of metalloprotease-1 (TIMP-1) [5–9].(MAP) was monitored: group 1, 600 ng/kg/min Ang II; group
PAI-1 is a member of the superfamily of serine protease2, Ang II 1 10 mg/kg of the AT1 receptor antagonist (AT1RA)
L158-809 q2 hour; group 3, Ang II 1 0.01 to 0.1 mg/kg hydral- inhibitors and is the primary physiologic inhibitor of
azine as required to maintain normal blood pressure; and group tissue-type PA (t-PA) and urokinase-type PA (u-PA) [10].
4, saline-infused controls. After infusion, tissue was harvested
Plasmin is generated from the inactive precursor plas-for Northern blotting, immunohistochemical analysis, and in
minogen by the action of plasminogen activators. Plas-situ hybridization.
Results. In group 1, Ang II infusion increased MAP from min’s broad proteolytic activity makes it important in
105 6 8 to 160 6 9 mm Hg (mean 6 SE, P , 0.01). Ang II wound repair, ECM degradation, and fibrinolysis. Plas-
induced increased expression of PAI-1 mRNA in all tissues min plays an additional role in regulating ECM deposi-examined from 5.1-fold in the heart, 9.7-fold in the kidney,
tion by activation of latent matrix metalloproteinases10.0-fold in the aorta, and up to 30.0-fold in the liver (all P ,
(MMPs) [11], which degrade ECM proteins in the kid-0.01 vs. control). While both AT1RA (group 3) and hydralazine
(group 4) prevented Ang II-induced elevation in blood pres- ney. Thus, it is not surprising that PAI-1 influences the
sure, the Ang II-dependent expression of PAI-1 mRNA was development of fibrosis in tissues and that PAI-1 defi-
reduced by only AT1 receptor blockade.
ciency protects mice from bleomycin-induced pulmonaryConclusions. We conclude that in the rat, PAI-1 is induced
fibrosis [12]. We have hypothesized that the well-recog-in a variety of tissues by Ang II directly through the AT1
receptor, independent of its effects on blood pressure. nized effects of Ang on fibrosis may be augmented by
its actions to induce PAI-1 [13, 14]. In vitro data have
shown that the AT1 receptor mediates this Ang-induced
Activation of the renin-angiotensin system (RAS) is
PAI-1 expression in vascular smooth muscle cells, whileassociated with vascular and glomerular sclerosis and
the Ang II-derived hexapeptide metabolite, Ang IV, act-
ing through the AT4 receptor, regulates PAI-1 expres-
1 See Editorial by Basile, p. 460 sion in bovine aortic endothelial cells [5–7]. In contrast, in
vivo data have shown that both Ang I-converting enzymeKey words: renin-angiotensin system, plasmin/plasminogen activator
system, extracellular matrix, blood pressure. inhibitor (ACEI) and an Ang type 1 receptor antagonist
(AT1RA) were associated with decreased scarring and
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decreased PAI-1 expression in a renal model of sclerosisand in revised form January 10, 2000
Accepted for publication February 1, 2000 [14]. However, the specific mechanisms for Ang II induc-
tion in vivo of PAI-1 have not been previously examined.Ó 2000 by the International Society of Nephrology
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The present study was performed in order to identify E. coli as previously described [14]. Fidelity of the cDNA
product was confirmed by DNA sequence analysis. Theand characterize the induction of PAI-1 by Ang II in vivo
and to determine whether hemodynamic effects were commercial human glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) cDNA probe was used as a housekeep-involved with this effect.
ing gene control (Promega, Madison, WI, USA). cDNA
probes were labeled with [32P]dCTP (New England Nu-
METHODS
clear, Boston, MA, USA) by the random primer method.
Experimental design and animals
RNA isolation and Northern blot hybridizationAdult male Sprague-Dawley rats (N 5 25, 350 to 450 g;
Charles River, Nashville, TN, USA) were studied. Ani- Total RNA from left kidney, liver, heart, and aortic
tissues were extracted by RNAzoleB method (Cinna Bio-mals were housed under normal conditions with a 12-
hour light/dark cycle at 708F with 40% humidity and 12 tecx, Houston, TX, USA). RNA pellets were resuspended
in DEPC-treated water, and RNA concentration wasair exchanges/hour. Rats received normal rat chow and
water ad libitum (“5001” Purina Laboratory Rodent diet, determined by absorbance at 260 nm. RNA (15 mg) was
size fractionated on 1.0% formaldehyde agarose gels.23.4% protein, 4.5% fat, 6.0% fiber, and 0.40% sodium)
before the study. All studies were approved by the Insti- Equal loading of RNA was confirmed by visual examina-
tion of ribosomal RNA by ethidium bromide staining.tutional Animal Care and Use Committee.
Rats were anesthetized with 50 mg/kg inactin intraper- RNA was transferred to nylon membranes (Hybond N;
Amersham, Piscataway, NJ, USA) and cross-linked byitoneally (Byk, Gulden Konstanz, Germany) and placed
on a temperature-controlled table set at 378C. Polyethyl- ultraviolet illumination. The membranes were incubated
in prehybridization buffer for two hours and then hybrid-ene catheters were placed in the right femoral vein and
artery for continuous infusion and monitoring of arterial ized with [32P] dCTP-labeled cDNA probes for 18 to 24
hours at 658C in hybridization buffer [4 3 SSCP, 1 3blood pressure by a transducer recorder (Blood Pressure
Analyzer 100; Micro-Med Inc., Louisville, KY, USA). Denhardt’s, 1 3 sodium dodecyl sulfate (SDS), 100
mg/mL denatured salmon sperm DNA, and 10% dextranAll rats were treated with four hours of continuous intra-
venous infusions at 1.0 mL/h rates as specified later in sulfate]. Membranes were washed twice in 2 3 standard
saline citrate (SSC), 0.1% SSC for 20 minutes at 658Cthis article. The dose of Ang II was chosen based on pilot
studies for maximum induction of PAI-1 while being able and once in 0.1 3 SSC, 0.1% SSC for 20 minutes at 658C.
Membranes were air dried and exposed to XAR filmto control blood pressure with hydralazine (doses from
200 ng/kg/min; data not shown). All compounds were (Kodak Co., Rochester, NY, USA) in intensifying screens
at 2708C for three to five days. Autoradiographs weredissolved in 0.9% sterile sodium chloride solution. Mean
arterial pressure (MAP) was monitored continuously scanned by image scanner JX-330 (Sharp, Japan), and
the intensity of signals was measured by NIH Imagethroughout the study period. There were five animals in
each treatment group. Group 1 was infused with Ang II, (National Institute of Health, Bethesda, MD, USA). The
ratio of specific message to the housekeeping gene600 ng/kg/min (Ang II acetate salt; Sigma, St. Louis, MO,
USA). Group 2 was infused with Ang II, 600 ng/kg/min 1 GAPDH was used to quantitate expression for each tis-
sue sample.L158-809, 10 mg/kg every 2 hours intravenously (highly
specific AT1RA, gift of Merck Research Laboratories
In situ hybridizationInc., Rahway, NJ, USA). Group 3 was infused with Ang
II, 600 ng/kg/min 1 hydralazine, 0.01 to 0.1 mg/kg intrave- 35S-labeled sense and antisense riboprobes for PAI-1
were prepared by transcription of the pCReII plasmidnously (Sigma), as required to maintain normal blood
pressure. Group 4 was infused with saline, 1.0 mL/hour with insertion of cDNA fragment by SP6 or T7 RNA
polymerase as previously described (Promega) [14]. Sec-(control).
Rats were sacrificed immediately after the end of the tions were dewaxed in xylene and hydrated in graded
ethanols and then 4% paraformaldehyde. After treat-four hours of infusion, and kidney, liver, heart, and aorta
were harvested. Tissues for morphological studies were ment by proteinase K and triethanolamine/acetic anhy-
dride, sections were dehydrated in ethanol and air dried.immersion fixed in 4% paraformaldehyde-phosphate-
buffered saline (PBS) solution. Portions of tissues were Hybridization was done in buffer [50% formamide,
10% dextran sulfate, 8 mmol/L dithiothreitol (DTT),homogenized in isopropanol for precipitation of RNA.
0.2 mg/mL tRNA, 300 mmol/L NaCl, 10 mmol/L Tris-
cDNA probes HCl, 5 mmol/L ethylenediaminetetraacetic acid (EDTA),
0.02% polyvinylpyrolidone, 0.02% Ficoll, and 0.02%The cDNA fragment for rat PAI-1 mRNA was pre-
pared by reverse transcription-polymerase chain reaction BSA) overnight at 508C. Sections were washed in 5 3
SSC, 20 mmol/L b-mercaptoethanol at 508C for 15 min-(RT-PCR) and cloned using a TA cloning kit (Invitrogen,
Carlsbad, CA, USA), and harvested and purified from utes, in 2 3 SSC, 200 mmol/L b-mercaptoethanol, 50%
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formamide at 688C for 20 minutes, in TEN twice at 378C
for 10 minutes, treated with RNase at 378C for 30 min-
utes, washed in TEN at 378C for 10 minutes, in 2 3 SSC,
and 0.1 3 SSC each twice at 688C for 15 minutes. Sections
were then dehydrated in ethanol and air dried, dipped
in photographic emulsion, and exposed at 48C for 10
days. The sections were developed with D-19 developer
(Kodak) and counterstained with toluidine blue. Control
in situ hybridization was done with sense probes.
Immunohistochemistry
Tissues were routinely processed, and 4 m sections Fig. 1. Mean arterial pressure (MAP) data during infusions are shown.
were prepared. Sections were treated by 3% hydrogen Angiotensin II (Ang II) resulted in a significant increase in MAP.
Both Ang II type 1 receptor antagonist (AT1RA) and hydralazine (H)peroxidase for 10 minutes, power block (BioGenex Lab-
normalized MAP, although only AT1RA decreased PAI-1 expression.
oratories, San Ramon, CA, USA) for 45 minutes, and
then incubated with 20 mg/mL rabbit antirat PAI-1 anti-
body overnight (American Diagnostica Inc., Greenwich,
CT, USA). This antibody has been previously character- in group 3; P 5 NS vs. control, P 5 NS group 2 vs. group
ized and shown to be specific for PAI-1 [15]. After rinsing 3; Fig. 1).
twice with PBS, biotinylated goat antirabbit Ig (Bio-
Effects of Ang II on PAI-1 expressionGenex) was added, incubated for 45 minutes, followed by
rinsing two times in PBS, and incubation with peroxidase PAI-1 expression by Northern blot. The expression of
conjugated streptavidin (BioGenex) for 45 minutes. PAI-1 mRNA was increased in all tissues examined in
After rinsing three times with PBS, diaminobenzidine response to Ang II infusion. The expression of PAI-1
was added as a chromagen. Slides were counterstained mRNA relative to GAPDH was increased by Ang II
with hematoxylin. Control slides treated with nonspecific versus saline control 9.7-fold in kidney (arbitrary density
antisera instead of the primary antibody showed no stain- units 1.93 6 0.74 vs. 0.20 6 0.08), 5.1-fold in heart (1.63 6
ing. All sections were examined without knowledge of 0.29 vs. 0.32 6 0.08), 10.0-fold in aorta (2.30 6 0.52 vs.
the treatment protocol. 0.25 6 0.11), and 30.0-fold in liver (3.90 6 0.86 vs. 0.13 6
0.02, all P , 0.01 vs. control; Fig. 2). The PAI-1/GAPDH
Statistical analysis mRNA ratio was thus significantly increased in group 1
The average of ratios of PAI-1 mRNA and GAPDH Ang II-infused rats versus control saline. The increased
for each group was compared using Fisher’s PLSD fol- expression of PAI-1 mRNA in response to Ang II in
lowed by analysis of variance (ANOVA). Results are these tissues was completely abolished by the AT1RA
presented as means 6 SE. A P value ,0.05 was consid- (group 2: PAI-1/GAPDH mRNA ratios for kidney, heart,
ered significant. aorta, and liver 0.8-, 0.8-, 1.2-, and 1.5-fold vs. control,
arbitrary density units 0.16 6 0.10, 0.25 6 0.13, 0.31 6
0.09, and 0.20 6 0.14 in each organ, respectively, all P 5RESULTS
NS vs. control; Fig. 3). In contrast, the expression of
Effect of Ang II on MAP PAI-1 mRNA in response to Ang II was not attenuated
Angiotensin II infusion alone (group 1) resulted in in- when MAP was normalized by hydralazine (Fig. 4). The
creased MAP, from baseline 105 6 8 to 160 6 9 mm Hg PAI-1/GAPDH mRNA ratios were significantly higher
(P , 0.01; Fig. 1). In contrast, saline-infused controls than control saline in group 3 animal tissues (PAI-1/
(group 4) exhibited no significant change in MAP during GAPDH mRNA ratios for kidney, heart, aorta, and liver
the study period (baseline 106 6 9 vs. 107 6 14 mm Hg 9.3-, 3.9-, 8.1-and 21.5-fold, respectively, vs. control; arbi-
at end of infusion, P 5 NS). In order to examine whether trary density units 1.85 6 0.43, 1.23 6 0.29, 2.03 6 0.96,
any induction of PAI-1 mRNA was blood pressure de- and 2.79 6 0.85 in each organ, all P , 0.05 vs. control)
pendent or mediated by nonhemodynamic actions of the and not different from Ang II alone (P 5 NS; Fig. 5).
AT1 receptor, Ang II-infused rats were treated with an PAI-1 expression by in situ hybridization and immuno-
AT1RA, L158,809 (group 2), or hydralazine (group 3), histochemistry. There was minimal expression of PAI-1
to normalize MAP during Ang II infusion. These agents mRNA by in situ hybridization in group 4 saline control
effectively prevented the pressor responses to Ang II infusion rats, with low-level signal diffusely over all tu-
(baseline 95 6 9 vs. 93 6 9 mm Hg after infusion in bules in the kidney, without a specific signal in glomeruli,
endothelium, collecting duct, or smooth muscle of pelvisgroup 2; baseline 103 6 5 vs. 97 6 8 mm Hg after infusion
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Fig. 2. After infusion of Ang II, the expres-
sion of PAI-1 mRNA was increased in all tis-
sues. Control saline did not induce plasmino-
gen activator inhibitor-1 (PAI-1) mRNA.
PAI-1/GAPDH ratio was significantly in-
creased in Ang II versus control saline. (Each
lane represents mRNA from one rat. North-
ern blots from three rats representative of the
entire group are shown.)
at the vascular pole of the glomerulus, mesangial and
parietal epithelial cells, and endothelial cells (Fig. 6 b,
d, f, j, l). The strongest signals were present in collecting
duct, smooth muscle layer of pelvis, and fat tissue around
the pelvis. In the heart in group 1 rats, PAI-1 signal
was diffusely distributed in myocytes, with even stronger
signal in myocytes at the boundary between right and
left ventricle, and portions of right ventricular wall (Fig.
6f). In the aorta, PAI-1 signal was present in endothelial
cells and in the outer portion of the vascular smooth
muscle cell layer after Ang II infusion (Fig. 6d). In theFig. 3. Expression of PAI-1 mRNA was attenuated in Ang II 1
liver, PAI-1 signal was expressed diffusely in hepatocytesAT1RA in all tissues analyzed. The PAI-1/GAPDH ratio was signifi-
cantly decreased compared with Ang II (P , 0.01), but was not different after Ang II infusion. These signals were decreased with
from control saline (P 5 NS vs. control, representative Northern blots). AT1RA in group 2 to patterns comparable to control
(Fig. 6h). Immunostaining in saline-infused control ani-
mals showed low-level staining in all tissues without in-
creased staining at any specific sites (data not shown).
Immunohistochemistry in Ang II-infused rats showed
PAI-1 protein present in a distribution similar to that of
its mRNA (Fig. 6 a, c, e), while staining was indistinguish-
able from control saline-infused rats when animals also
received hydralazine (data not shown). No specific signal
was detected with sense probe (data not shown). No
specific immunostaining was detected when nonspecific
primary antibody was used (data not shown).
DISCUSSION
In the current study, we demonstrate that Ang IIFig. 4. The increased expression of PAI-1 mRNA in response to Ang
II was not attenuated when MAP was normalized by hydralazine acutely induces PAI-1 expression in the rat. This effect
(representative Northern blots). of Ang II is largely mediated via the AT1 receptor and
appears to be independent of blood pressure effects,
although a minor component contributed to by local
pressure effects cannot be definitively excluded based(Fig. 6 g, i, k). Minimal signal was present in the heart
on our measurements of systemic blood pressure. Thus,with occasional signal over endocardium and myocar-
normalization of Ang II-induced hypertension with hy-dium, and likewise, minimal signal was present in aorta
dralazine had no effect on PAI-1 induction. This induc-and liver (data not shown). In Ang II-treated animals
tion by Ang II of PAI-1 may be a key contributor to(group 1), PAI-1 mRNA signals in the kidney were pres-
ent in the smooth muscle layer of pelvis, collecting duct, the effects of Ang II in promoting tissue injury and/or
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Fig. 5. Quantitative assessment for PAI-1/GAPDH ratios from all rats in all groups in (A) kidney, (B) liver, (C) heart, and (D) aorta is shown.
*P , 0.01; #P , 0.05 vs. Ang II or Ang II 1 hydralazine (H).
blunting reparative responses. Although activation of Activation of the RAS has previously been shown to
the RAS is generally associated with increased fibrosis, induce multiple growth factors that have been implicated
there is substantial evidence that inhibition of the RAS in fibrosis, such as transforming growth factor-b (TGF-b)
ameliorates progressive renal injury beyond that which and platelet-derived growth factor-B (PDGF-B) [3, 18–
can be attributed to blood pressure effects alone [1, 3, 20]. Induction of these growth factors appears to be
16]. In the 5/6 nephrectomy hypertensive rat model of mediated by Ang II acting at the AT1 receptor [21].
progressive renal disease, simple blood pressure reduc- TGF-b itself is known to regulate PAI-1 expression
tion with hydralazine failed to attenuate glomeruloscle- through a Smad-dependent signaling pathway [22]. How-
rosis, while ACEI or AT1RA (with similar systemic ever, the early induction of PAI-1 by Ang II in vitro
blood pressure effect) were effective in this regard [17]. in mesangial cells is TGF-b independent [23]. The link
In the nonhypertensive radiation nephropathy rat model,
between the RAS and the PAI-1 proteolytic pathwayboth ACEI and AT1RA completely prevented tissue
has only been recognized more recently, but may be ainjury [14]. These results show that inhibition of the
key mechanism of Ang II-induced injury [24]. We haveRAS can attenuate tissue injury via the AT1 receptor
previously shown that the hexapeptide metabolite ofindependently of antihypertensive actions and suggest
Ang II, Ang IV, stimulates PAI-1 expression in vitrothat merely controlling blood pressure with nonspecific
[6, 7]. This relationship between Ang and PAI-1 wasantihypertensives may not have the same antifibrotic
also demonstrated in animal studies with aortic injurypotential. The implication follows that the local RAS,
[25] or renal microvascular injury induced by radiationrather than only systemic blood pressure, may play a
predominant role in the development of sclerosis. [14]. The colocalization of injury with increased PAI-1
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Fig. 6. Rats infused with Ang II (group 1) showed increased PAI-1 expression by in situ hybridization and immunohistochemistry in kidney (a,
b, j, and l ), aorta (c and d ), and heart (e and f ). In the glomerulus, PAI-1 immunostaining was detected at the vascular pole, in mesangial areas,
endothelial cells, and parietal epithelial cells (a). The distribution of glomerular PAI-1 mRNA expression (b) was in a pattern similar to that of
the protein. Treatment with the AT1RA (h) decreased these signals to patterns comparable to control saline treated animals (g). Strong signals
were also present in kidney in response to Ang II in the collecting duct ( j), smooth muscle layer of pelvis (l), and fat tissue around the pelvis, in
comparison with minimal background signal in control saline-infused animals (i and k). Aortic endothelial cells and outer layer vascular smooth
muscle cells showed PAI-1 mRNA expression and positive immunostaining (c and d). Myocytes showed scattered intense signal for PAI-1 mRNA
and positive immunostaining (e and f). (a, c, and e) Immunostaining with anti-PAI-1 antibody. (b d, and f–l) In situ hybridization with antisense
probe for PAI-1 mRNA (magnifications a, 3200; b–d and g–l 3400; e and f, 3100).
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Fig. 6. (Continued).
expression supports a pathogenic role for PAI-1 in tissue duced in PAI-1 knockout mice when compared with
wild-type controls [12]. Studies in humans also show aninjury [14]. Furthermore, the prevention of injury in the
radiation model by either an AT1 antagonist or ACEI effect of Ang II on PAI-1. Infusion of Ang II in patients
specifically induced PAI-1 plasma levels and activitywas tightly linked to decreased, albeit not normalized,
PAI-1 expression [14]. Studies in PAI-1 knockout mice without affecting t-PA levels [26]. Activation of the en-
dogenous RAS is also associated with increased plasmaalso support a role for PAI-1 in tissue injury. Pulmonary
fibrosis in response to bleomycin was significantly re- PAI-1 levels in humans [27]. Conversely, ACEI in pa-
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studies point to adverse consequences of increased
PAI-1 levels, with an association with increased cardio- REFERENCES
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